Hikma Pharmaceuticals PLC Annual report 2010 remunerAtion Committee rePort Continued name date of original appointment notice payment samih darwazah 17 July 2007 1 month michael Ashton 14 october 2005 1 month Ali Al-Husry 14 october 2005 1 month Breffni Byrne 14 october 2005 1 month ronald Goode 12 december 2006 1 month sir david rowe-Ham 14 october 2005 1 month total shareholder return performance graph The graph shows the Companys performance, measured by total shareholder return TSR, compared to the FTSE 250 Index and the FTSE 350 Pharmaceuticals & Biotechnology Index from 1 January 2006 to 31 January 2011.
The FTSE 250 and 350 Indices have been selected to provide abroader comparator of the Companys performance.
HIKMA FTSE 250 FTSE 350 PHARMACEU TICALS PHARMACEUTICALS PLC & BIOTECHNOLOGY 120 100 80 60 40 20 0 20 40 JAN 06 JUL 06 JAN 07 JUL 07 JAN 08 JUL 08 JAN 09 JUL 09 JAN 10 JUL 10 JAN 11 TOTAL SHARE HOLDER RETURN FROM 1 JANUARY 2006 % Audited information Aggregate Directors remuneration for 2010 and 2009 The total amounts for Directors remuneration were as follows: 2010 2009 us$ us$ emoluments 4,083,095 2,739,389 Compensation for loss of office - Gains on exercise of share options 1,248,654 4,644,835 Amounts receivable under long-term incentive schemes - money purchase pension contributions - Total 5,331,749 7,384,224 66 Section Four: Governance 4 Directors emoluments and compensation 2010 2009 fees Basic salary other Annual bonuses total total 1 director us$ benefits us$ us$ us$ Executives said darwazah 630,000 74,883 1,260,000 1,964,883 1,182,845 mazen darwazah 420,000 36,112 840,000 1,296,112 796,968 Non-Executives samih darwazah 243,538 243,538 245,693 Ali Al-Husry 96,752 96,752 93,431 michael Ashton 119,725 119,725 105,113 Breffni Byrne 131,247 131,247 116,795 2 ronald Goode 111,113 111,113 93,431 sir david rowe-Ham 119,725 119,725 105,113 Aggregate emoluments 1,872,100 110,995 2,100,000 4,083,095 2,739,389 1 Other Benefits include provision of health insurance, company car and medical expenses.
2 Dr Ronald Goode became Chairman of the Compliance, Responsibility and Ethics Committee in August 2010 and received the chairmanship fee of 7,500 per annum pro rated for one quarter.
Directors post-employment benefits Each of the Executive Directors received contributions to the Hikma Pharmaceuticals Defined Contribution Retirement Benefit Plan Jordan during the year under review.
The contributions paid by the Group were as follows: 2010 2009 director us$ us$ said darwazah 8,505 8,505 mazen darwazah 7,818 7,818 Directors interests in shares The table below details the Directors holdings in the share capital of the Company, including the changes between 31 December 2010 and the date of this document.
ordinary shares of 10 pence 1 January 31 december 15 march director 2010 2010 2011 samih darwazah 2,515,450 2,331,746 2,331,746 said darwazah 413,445 213,445 213,445 mazen darwazah 986,591 695,225 695,225 michael Ashton 18,566 18,566 18,566 Ali Al-Husry 1,109,748 1,109,748 1,109,748 Breffni Byrne 10,000 10,000 10,000 ronald Goode 9,000 12,700 12,700 sir david rowe-Ham 10,000 10,000 10,000 Total shares 5,072,800 4,401,430 4,401,430 Each of Samih Darwazah, Said Darwazah, Mazen Darwazah and Ali Al-Husry are directors of Darhold Limited, which is therefore a connected person of these individuals for the purposes of the Listing Rules and the Disclosure and Transparency Rules of the Financial Services Authority.
Samih Darwazah, Said Darwazah, Mazen Darwazah and Ali Al-Husry are also shareholders of Darhold Limited.
At the date of this document, Darhold Limited held 57,183,028 Ordinary Shares of the Company.
